Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Why Compounding Access Is Not an Established Path Positioning in the Metabolic Medicine Conversation For physicians fielding patient questions about 5-amino-1MQ, the appropriate framing: Promising mechanism with solid preclinical rationale Early clinical development human efficacy and safety not yet well characterized No legitimate clinical access pathway in the United States as of 2026 Alternative evidence-based options exist for the underlying metabolic optimization goals patients typically pursue Key Takeaways 5-amino-1MQ is a small-molecule NNMT inhibitor, not a peptide
If you're taking other medications, keep your healthcare provider informed to avoid any potential interactions
Over-the-counter options include oral tablets or nasal sprays
Human clinical trial activity is emerging
